We confirmed silencing of G6PD by immunobloting in LNCaP, C4-2, CWR22 and 22Rv1 cells and demonstrated that, like 6AN, molecular inhibition of G6PD decreased prostate cancer cell growth in the presence or absence of androgens in both hormone-sensitive and castration-resistant cell models (Figures 1c–f; Supplementary Figures 1C–F). Here, G6PD is linked to prostate cancer.